Portable decontamination units. infection containment units, Hazmat suits. Air filtration systems, Protective hoods, respirators, gloves, boots, face protectors, portable triage centers, 220 million backlog, blue light sanitation units, government contracts and only 8 million share float.
it went as high as 97, so were can CYBR run too? 3x as much?
Comments by President, Erwin of IBIO.
Giroir said the Texas center "is very familiar" with plant-based antibody production. If it wins a government contract for ZMapp production, it would likely tap Caliber Biotherapeutics, which specializes in tobacco-plant-based drug production and shares the Texas campus, as a subcontractor
Adam Havey, president of Emergent's biodefense division, said the company has been in discussions with plant-based manufacturers to develop a response to the task order.
IBIO going to $20
Ekso(TM) Clear Leader in Exoskeleton Comparison Study Presented at The International Workshop on Wearable Robotics
Bergmannstrost Center Sponsored Study Highlights Ease of Use and Range of Patient Population
7 minutes ago
RICHMOND, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (EKSO), a robotic exoskeleton company, announced today that Bergmannstrost Center in Halle, Germany, a leader in rehabilitation research, presented data today at The International Workshop on Wearable Robotics, WeRob2014 in Baiona, Spain showing the benefits of the Ekso(TM) robotic suit compared to ReWalk and Cyberdyne. The presentation followed recent publication of the article "Comparison of Therapy with the Exoskeletons ReWalk, Ekso and HAL" by Dr. Jane Nitschke and Dr. Klaus Rohl, which was published in German in the Journal Orthopadietechnik.
The presentation detailed the advantages of Ekso over other robotic exoskeletons in the clinical environment, citing the ease of changing from patient to patient in Ekso, the absence of skin injuries from using the Ekso Bionics(TM)device, and the operation of its Variable Assist(TM) software.
"Ekso was the best choice for us at this time for rehabilitation therapy," said Dr. Nitschke.
The release of this study comes on the heels of four centers in Germany recently ordering the Ekso robotic exoskeleton and after utilizing the Ekso GT and other competitors' devices with their patients. BG Bergmannstrost, BG Tubingen, BG Duisburg and RKU Ulm have all recently placed orders of the Ekso Bionics suit and the centers will use the Ekso GT robotic exoskeleton to perform gait training. The device uniquely offers gait training rehabilitation for complete SCI, incomplete SCI and non-or pre-ambulatory individuals post-stroke stroke patients using variable assistance and a hemiplegic mode that does not otherwise exist in the industry
I would also think SFTBY is the better buy since they are holding Alibaba for the long run to !000 like GOOG and PCLN
is spending a BILLION dollars for their phase1 IMMUNOTHERAPY drug. NWBO to $30 imo.
EKSO best of breed in this exoskeleton space.